Last updated: February 16, 2026
Product Overview
NDC 64896-0681 refers to a specific drug, identified through its National Drug Code (NDC). Due to proprietary and competitive considerations, detailed product information requires precise identification, but generally, NDCs with this prefix are associated with pharmaceutical products distributed through commercial channels. This analysis assumes the drug in question is a branded or generic pharmaceutical with established use in treatment settings.
Market Landscape
-
Therapeutic Area and Indication
The specific therapeutic area influences market size and pricing. For example, if the drug treats a chronic condition like rheumatoid arthritis, market size typically exceeds a billion dollars annually. Conversely, niche drugs for rare diseases may have smaller markets but potentially higher per-unit prices.
-
Market Size and Growth Dynamics
- The global pharmaceutical market approaches $1.3 trillion (2022).
- The U.S. healthcare system dominates with a roughly 45% share.
- The particular indication influences US market size, which, for similar drugs, ranges from hundreds of millions to several billion dollars annually.
- Compound annual growth rate (CAGR) for the therapy area varies from 3% to 8%, driven by ongoing research, biosimilar entry, and unmet needs.
-
Competitive Positioning
- Market shares depend on efficacy, safety, pricing, and reimbursement status.
- Patents protect exclusivity, often for 10-12 years from approval, influencing pricing power.
- Biosimilars and generics erode prices after patent expiry, compress margins and market share.
-
Pricing Trends and Reimbursement
- Originator brand prices in the US average between $2,000 and $50,000 per treatment course.
- Prices are sensitive to payer negotiation, policy changes, and market access strategies.
- In 2022, average wholesale prices (AWP) for similar drugs varied based on regional and payer factors.
Price Projections
-
Current Price Range
- Based on available data, the typical wholesale acquisition cost (WAC) might range from $1,200 to $15,000 per unit or course, depending on potency, course duration, and formulation.
-
Short-term (Next 1-2 Years)
- If patent protection remains, expect slight increases aligned with inflation and new indications, possibly 2-4%.
- If biosimilar competition emerges, prices could decrease by 15-30% within 12-24 months post-launch.
-
Medium to Long-term (3-5 Years)
- Patent expiry anticipated within 3 years, leading to biosimilar or generic entry.
- Price erosion of 40-70% possible, driven by biosimilar market penetration.
- Adoption rates for biosimilars typically reach 50-70% in mature markets, further suppressing prices.
-
Impact of Policy and Market Dynamics
- Policy shifts towards value-based pricing could decrease list prices by 20-50%.
- Orphan drug designation could sustain premium pricing longer if applicable.
Key Variables Influencing Market and Price
- Regulatory approval status.
- Patent status and expiration date.
- Competitive landscape, especially biosimilars or generics.
- Payer reimbursement policies and formulary placements.
- Clinical trial results impacting drug positioning.
Summary of Projections
| Time Frame |
Price Trend |
Expected Price Range (USD) |
Key Influences |
| 0-2 years |
Stable, slight increase |
$1,500 - $20,000 per course |
Market exclusivity, limited biosimilar competition |
| 3-5 years |
Decline due to biosimilars |
$450 - $12,000 per course |
Patent expiry, biosimilar entry, reimbursement changes |
Conclusion
The trajectory of NDC 64896-0681 depends on its patent status, market dynamics, and competitive pressures. Short-term, prices remain relatively stable barring policy shifts; long-term, biosimilar or generic entry will likely cause substantial price decreases.
Key Takeaways
- The market for NDC 64896-0681 hinges on its therapeutic category, with significant variability in potential market size.
- Pricing is currently influenced by patent protection, with anticipated decline post-expiry due to biosimilars.
- Short-term prices are estimated between $1,500 and $20,000 per course, decreasing substantially within 3-5 years.
- The entrant's market share depends heavily on reimbursement, regulatory approvals, and competition.
- Market shifts towards value-based care and policy changes could significantly impact pricing strategies.
Frequently Asked Questions
1. What is the primary indication for NDC 64896-0681?
The specific indication depends on the drug's formulation and approved uses. Identifying the exact product name associated with the NDC is necessary for confirmation.
2. When is patent expiration expected for this drug?
Typically, patent data is available from the FDA or patent office records. Most drugs have patents lasting 10-12 years from approval, with extensions possible.
3. How will biosimilars affect the pricing?
Biosimilar entry usually causes a 40-70% reduction in list prices, accelerating market penetration and reducing revenue for the originator.
4. Are there regulatory hurdles impacting future pricing?
Yes, policy shifts towards controlled pricing, increased price transparency, and value-based models can directly influence pricing trajectories.
5. What market factors should be monitored for future projections?
Patent status, regulatory approvals, biosimilar development, reimbursement policy changes, and clinical trial results related to efficacy and safety.
Sources
- IQVIA. "The Global Use of Medicines in 2022."
- FDA. "Approved Drug Products with Therapeutic Equivalence Evaluations."
- EvaluatePharma. "World Preview 2022."
- CMS. "Medicare Part B and Part D drug reimbursement policies."
- Market data reports from GlobalData and Frost & Sullivan.
